Paper37908366
Novel lipid antigens for NKT cells in cancer.
Lee MS and 1 other. Front Immunol, 2023. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Novel lipid antigens for NKT cells in cancer. Papers, record 37908366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37908366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Natural Killer T-Cells | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Antigen Presentation | |
| Lipids |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA134274 | NCI NIH HHS | United States | P30CA134274 | PubMed and NIH | NIH RePORTER |
| R25 GM113262 | NIGMS NIH HHS | United States | R25GM113262 | PubMed and NIH | NIH RePORTER |
References96
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22767159 | Lipidomic analysis of phospholipids from human mammary epithelial and breast cancer cell lines. | J Cell Physiol | 2013 | https://conductscience.org/library/papers/22767159 | PubMed |
| 2 | 26862848 | Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/26862848 | PubMed |
| 3 | 26297715 | The alpha and omega of galactosylceramides in T cell immune function. | J Biol Chem | 2015 | https://conductscience.org/library/papers/26297715 | PubMed |
| 4 | 28851309 | Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer. | BMC Cancer | 2017 | https://conductscience.org/library/papers/28851309 | PubMed |
| 5 | 21653685 | Enhanced antitumor effects by chemical modified IGb3 analogues. | Mol Cancer Ther | 2011 | https://conductscience.org/library/papers/21653685 | PubMed |
| 6 | 27297969 | Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses. | Pathog Dis | 2016 | https://conductscience.org/library/papers/27297969 | PubMed |
| 7 | 15197224 | The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. | J Exp Med | 2004 | https://conductscience.org/library/papers/15197224 | PubMed |
| 8 | 17339459 | CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. | J Immunol | 2007 | https://conductscience.org/library/papers/17339459 | PubMed |
| 9 | 30822302 | TLR9-mediated dendritic cell activation uncovers mammalian ganglioside species with specific ceramide backbones that activate invariant natural killer T cells. | PLoS Biol | 2019 | https://conductscience.org/library/papers/30822302 | PubMed |
| 10 | 12023333 | Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. | J Immunol | 2002 | https://conductscience.org/library/papers/12023333 | PubMed |
| 11 | 12847141 | Cross-presentation of disialoganglioside GD3 to natural killer T cells. | J Exp Med | 2003 | https://conductscience.org/library/papers/12847141 | PubMed |
| 12 | 17409402 | Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. | Cancer Res | 2007 | https://conductscience.org/library/papers/17409402 | PubMed |
| 13 | 22932803 | NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. | Blood | 2012 | https://conductscience.org/library/papers/22932803 | PubMed |
| 14 | 14557411 | The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells. | J Exp Med | 2003 | https://conductscience.org/library/papers/14557411 | PubMed |
| 15 | 16087713 | Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. | J Exp Med | 2005 | https://conductscience.org/library/papers/16087713 | PubMed |
| 16 | 23100308 | Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. | Blood | 2013 | https://conductscience.org/library/papers/23100308 | PubMed |
| 17 | 23039336 | Comprehensive lipidome profiling of isogenic primary and metastatic colon adenocarcinoma cell lines. | Anal Chem | 2012 | https://conductscience.org/library/papers/23039336 | PubMed |
| 18 | 26969612 | The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction. | Cancer Immunol Immunother | 2016 | https://conductscience.org/library/papers/26969612 | PubMed |
| 19 | 3496420 | Developmentally regulated expression of T cell receptor beta chain variable domains in immature thymocytes. | J Exp Med | 1987 | https://conductscience.org/library/papers/3496420 | PubMed |
| 20 | 29163518 | Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy. | Front Immunol | 2017 | https://conductscience.org/library/papers/29163518 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42558863 | Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/42558863 | PubMed |
| 41908667 | Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms. | Cancer Pathog Ther | 2026 | https://conductscience.org/library/papers/41908667 | PubMed |
| 41827836 | Innate-like T Cell Biology in the Tumor Microenvironment Implications for Cancer Immunotherapy. | Cells | 2026 | https://conductscience.org/library/papers/41827836 | PubMed |
| 41375063 | Natural Killer (NK) Cell-Based Therapies Have the Potential to Treat Ovarian Cancer Effectively by Targeting Diverse Tumor Populations and Reducing the Risk of Recurrence. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41375063 | PubMed |
| 41200171 | Innate immunity in tumors: roles and therapeutic targets. | Front Immunol | 2025 | https://conductscience.org/library/papers/41200171 | PubMed |
| 41194129 | Innovative gene engineering strategies to address tumor antigen escape in cell therapy. | J Transl Med | 2025 | https://conductscience.org/library/papers/41194129 | PubMed |
| 41148807 | Evolutionary Perspective of Nonclassical MHC Class I and Innate-like T Cells Relevance in Immune Surveillance. | Cells | 2025 | https://conductscience.org/library/papers/41148807 | PubMed |
| 40746558 | Unconventional T cells in anti-cancer immunity. | Front Immunol | 2025 | https://conductscience.org/library/papers/40746558 | PubMed |
| 40718496 | CAR-iNKT cells: redefining the frontiers of cellular immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40718496 | PubMed |
| 40698085 | Global trends and frontiers in iNKT cells: a bibliometric and visualized analysis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40698085 | PubMed |
| 40583406 | NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy. | Immunotherapy | 2025 | https://conductscience.org/library/papers/40583406 | PubMed |
| 40456901 | Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/40456901 | PubMed |
| 40095325 | OMIP-111: Immune-Profiling of T Helper 1 (Th1), Th2, and Th17 Signatures in Murine Splenocytes by Targeting Intracellular Cytokines. | Cytometry A | 2025 | https://conductscience.org/library/papers/40095325 | PubMed |
| 39537239 | CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. | Gut | 2025 | https://conductscience.org/library/papers/39537239 | PubMed |
| 39508915 | SPINK5 is a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39508915 | PubMed |
| 39170618 | Traversing the bench to bedside journey for iNKT cell therapies. | Front Immunol | 2024 | https://conductscience.org/library/papers/39170618 | PubMed |
| 38885470 | NKT Cells and Other Innate T Cells: The Immune Cells That Do Not Follow the Rules. | J Immunol | 2024 | https://conductscience.org/library/papers/38885470 | PubMed |
| 38736328 | Human CD4+ iNKT cell adoptive immunotherapy induces anti-tumour responses against CD1d-negative EBV-driven B lymphoma. | Immunology | 2024 | https://conductscience.org/library/papers/38736328 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37908366
GET https://conductscience.org/api/papers/v1/37908366/references?page=2